San Francisco, CA, United States of America

Jesse Cedarbaum

USPTO Granted Patents = 2 

 

 

Average Co-Inventor Count = 1.6

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2014-2019

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Jesse Cedarbaum: Innovator in ALS and Hyperuricemia Treatments

Introduction

Jesse Cedarbaum is a notable inventor based in San Francisco, CA (US). She has made significant contributions to the fields of medicine and pharmacology, particularly in the treatment of amyotrophic lateral sclerosis (ALS) and hyperuricemia. With a total of 2 patents, Cedarbaum's work has the potential to impact many lives.

Latest Patents

Cedarbaum's latest patents include a method for treating ALS, which involves administering a therapeutically effective amount of riluzole and CK-2017357. This innovative approach aims to reduce the variability of riluzole exposure in subjects, decrease the total daily dose, and improve the overall treatment experience by minimizing adverse events. Additionally, she has developed methods for treating hyperuricemia and associated diseases, utilizing scyllo-inositol to effectively lower uric acid levels in individuals.

Career Highlights

Throughout her career, Cedarbaum has worked with prominent companies such as Cytokinetics, Inc. and Elan Pharmaceuticals, Inc. Her experience in these organizations has allowed her to refine her expertise and contribute to groundbreaking research in her field.

Collaborations

Cedarbaum has collaborated with esteemed colleagues, including John Mao and Fady Malik. These partnerships have fostered an environment of innovation and have led to the development of her impactful patents.

Conclusion

Jesse Cedarbaum's contributions to ALS and hyperuricemia treatments exemplify her dedication to advancing medical science. Her innovative patents and collaborations highlight her role as a significant figure in the field of pharmacology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…